Wegovy and NSAIDs (Ibuprofen, Naproxen): What the Interaction Actually Means for You

Is Wegovy plus ibuprofen or naproxen a drug interaction?

Semaglutide is a GLP-1 receptor agonist. It is broken down by proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty acid side chain, not by CYP enzymes [1]. Ibuprofen and naproxen are not named in the Wegovy drug interactions section, which covers two things: insulin or insulin secretagogues, where the concern is hypoglycemia, and oral medicines in general, where the concern is delayed gastric emptying [1].

The label says Wegovy delays gastric emptying and may therefore affect absorption of oral medicines, and it says to monitor the effects of oral medicines taken with it, considering increased clinical or laboratory monitoring for medicines with a narrow therapeutic index or that require clinical monitoring [1]. In clinical pharmacology trials with semaglutide 1 mg once-weekly injection, absorption of orally administered medicines was not affected. In a separate tablet interaction study, levothyroxine exposure rose 33% [1].

Ibuprofen and naproxen are not among the oral medicines named in the label's interaction findings, so the risk picture here comes from what each drug does on its own.

What does the NSAID label warn about?

Every prescription NSAID carries a boxed warning for serious GI bleeding, ulceration and perforation of the stomach or intestines, which can be fatal and can occur at any time without warning symptoms [2]. The label puts upper GI ulcers, gross bleeding or perforation at about 1% of patients treated for 3 to 6 months and 2% to 4% of those treated for a year [2]. Only one in five patients with a serious upper GI event has symptoms [2].

NSAID users with a past peptic ulcer or GI bleed have a more than 10-fold higher risk of a GI bleed than people without either of those risk factors [2]. Other factors that increase NSAID-related GI bleeding risk include longer treatment, corticosteroids or anticoagulants, smoking, alcohol use, and older age [2].

The CNT Collaboration meta-analysis of individual participant data from randomized trials found upper GI complications rose roughly fourfold versus placebo with both ibuprofen (RR 3.97, 95% CI 2.22 to 7.10) and naproxen (RR 4.22, 2.71 to 6.56) [4].

What Wegovy does to the stomach

Wegovy's labeled GI effects are a different kind of problem. In pooled 68-week trials of Wegovy 2.4 mg in adults with obesity or overweight, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%; any GI reaction occurred in 73% versus 47%, and 6.8% versus 3.2% stopped treatment because of adverse reactions [1]. The label also warns about severe GI adverse reactions, says Wegovy is not recommended in patients with severe gastroparesis, and lists ileus and intestinal obstruction among postmarketing reports [1].

The NSAID label's main GI concern is mucosal bleeding and ulceration; Wegovy's is nausea, vomiting and slowed transit.

Kidneys and blood pressure

NSAIDs block prostaglandin production, and the labels tie their kidney, diuretic and lithium effects to inhibition of renal prostaglandin synthesis [2]. Long-term use has caused renal papillary necrosis, and NSAIDs can cut renal blood flow in people who depend on renal prostaglandins. The highest-risk groups named in the label are people with impaired kidney function, dehydration, low blood volume, heart failure, liver dysfunction, diuretic or ACE inhibitor or ARB use, and older adults [2]. Hyperkalemia has been reported even without kidney impairment, and NSAIDs can start or worsen high blood pressure, cause fluid retention and edema, and about double heart-failure hospitalizations versus placebo [2]. The labels say to avoid NSAIDs in severe heart failure or advanced kidney disease unless the benefit outweighs the risk [2].

Wegovy's kidney warning runs through fluid loss. The label lists acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. In the Wegovy trials, acute kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in patients with prior renal impairment and during dose titration, and often after GI fluid loss [1].

A UK nested case-control study of 487,372 antihypertensive users did not involve Wegovy, but it shows how NSAIDs affect kidney risk alongside other kidney-active drugs. Adding an NSAID to a diuretic plus an ACE inhibitor or ARB gave an acute kidney injury rate ratio of 1.31 (95% CI 1.12 to 1.53), rising to 1.82 (1.35 to 2.46) in the first 30 days. An NSAID plus just one of those drugs was not associated with a higher rate overall [5].

What if you also take a blood thinner or low-dose aspirin?

Anticoagulants and NSAIDs are a labeled bleeding pair. In the EINSTEIN venous thromboembolism data, 8,246 patients on rivaroxaban or enoxaparin plus a vitamin K antagonist had clinically relevant bleeding at 37.5 versus 16.6 per 100 patient-years when taking an NSAID (hazard ratio 1.77, 1.46 to 2.14), and major bleeding at 6.5 versus 2.0 per 100 patient-years (hazard ratio 2.37, 1.51 to 3.75) [3].

Low-dose aspirin adds a separate problem. The ibuprofen label describes interference with aspirin's antiplatelet effect, seen with ibuprofen 400 mg three times daily alongside enteric-coated low-dose aspirin and even with once-daily ibuprofen 400 mg, particularly when ibuprofen is taken before aspirin. The label advises that people taking low-dose aspirin for heart protection who need an analgesic consider an NSAID that does not interfere, or a non-NSAID analgesic [2]. In a crossover study in healthy volunteers, ibuprofen 400 mg taken before aspirin blocked aspirin's platelet inhibition, while rofecoxib, acetaminophen and diclofenac did not [7].

Does pregnancy change the answer?

The FDA advised in October 2020 that NSAIDs be avoided at 20 weeks of pregnancy or later, because they can cause fetal kidney problems and low amniotic fluid; prescription labels limit use between about 20 and 30 weeks to the lowest effective dose and shortest time and avoid it from about 30 weeks [8]. The Wegovy label says weight loss offers no benefit in pregnancy and may cause fetal harm, that Wegovy should be discontinued when pregnancy is recognized if used for weight reduction, and that it should be discontinued at least 2 months before a planned pregnancy [1].

Are acetaminophen or a topical NSAID options?

The 2019 American College of Rheumatology and Arthritis Foundation osteoarthritis guideline conditionally recommends acetaminophen and strongly recommends topical NSAIDs for knee osteoarthritis [9]. Acetaminophen is not an NSAID, so the NSAID boxed warnings do not describe it.

Among oral NSAIDs, a Cochrane review found COX-2 selective inhibitors produced fewer clinically important ulcer complications than nonselective NSAIDs (relative risk 0.39, 95% CI 0.31 to 0.50) [10], and in the PRECISION trial celecoxib had fewer GI events than naproxen or ibuprofen, though celecoxib still carries a prescription NSAID boxed warning [11][2].